Group 1 - CRISPR Therapeutics AG (NASDAQ:CRSP) is projected to have significant growth potential, with analysts suggesting it could increase tenfold over the next decade [1] - Piper Sandler raised its price target for CRISPR Therapeutics AG to $110 from $105, maintaining an Overweight rating following the company's issuance of $600 million in convertible notes due in March 2031 [1] - The convertible notes are convertible at $76.56 per share and carry an effective interest rate of 1.73%, with an option for initial purchasers to acquire an additional $50 million in notes [1] Group 2 - CRISPR Therapeutics AG plans to disclose Phase I data on zugo-cel for autoimmune diseases and B-cell lymphoma in the latter half of 2026 [3] - The company will initiate Phase I research on CTX340 in the first half of 2026 and CTX460 in mid-2026, along with providing Phase Ib data on CTX310 and proof-of-concept Phase II data on CTX611 in patients undergoing total knee replacement in the second half of 2026 [3] - CRISPR Therapeutics AG is recognized as a leader in gene-editing technology, utilizing its proprietary gene sequencing platform to develop targeted treatments for diseases that require DNA modification [4]

Core Insights - CRISPR Therapeutics (CRSP) shares have declined approximately 11% since the start of 2026, but there are positive indicators for future growth, including significant investments from Cathie Wood [1] - Analysts at Piper Sandler have raised the price target for CRSP stock to $110, supported by a recent $600 million convertible note offering, which enhances the company's cash position to $2.56 billion [3] - The FDA-approved gene-editing therapy Casgevy has generated $116 million in revenue for 2025, with potential for market expansion through pediatric label approvals [4] Financial Position - CRISPR Therapeutics has completed a $600 million convertible note offering due in March 2031, convertible at $76.56 with a 1.73% effective coupon [3] - The company now holds pro forma cash of $2.56 billion, enabling it to advance multiple pipeline programs without the need for additional capital [3] Product Pipeline and Development - Casgevy is a key product for CRISPR, approved for treating sickle cell disease and beta-thalassemia, with significant revenue generation and potential for market expansion [4] - The company is expanding its research beyond Casgevy into cardiovascular, autoimmune, and oncological indications, with promising early results from CTX310 and ongoing trials for CTX112 and CTX611 [5][6] - CTX310 has shown a 49% reduction in LDL cholesterol and a 55% reduction in triglycerides over 60 days, indicating strong efficacy and safety [5] - CTX611 is in Phase 2 trials targeting thromboembolic and clotting-related indications, representing a multi-billion-dollar market opportunity [6]

Summary of CRISPR Therapeutics FY Conference Call Company Overview - **Company**: CRISPR Therapeutics (NasdaqGM:CRSP) - **Date**: March 02, 2026 - **Key Speaker**: Samarth Kulkarni, Chairman and CEO Core Industry Insights - **Transition Focus**: CRISPR is shifting from a technology-backed company to a disease-backed company, emphasizing a diverse pipeline beyond its lead product, Casgevy [3][4] - **Pipeline Value**: Approximately one-third of the company's value is attributed to Casgevy, with another third from promising Phase 1 assets (CTX310, CTX320, CTX611) [4] - **Future Programs**: By mid-2027, CRISPR anticipates data for six programs across more than six indications beyond Casgevy [4] Key Business Segments - **Cardiovascular**: - Programs include CTX310, CTX611, and CTX340 targeting refractory hypertension [5][6] - **Autoimmune**: - Focus on CTX320 and additional siRNA targets in the autoimmune space [5][6] - **Other Areas**: - Development in Type One diabetes and oncology [6] Casgevy Sales and Market Dynamics - **2025 Sales**: Casgevy achieved over $100 million in sales for 2025, with expectations for continued growth in 2026 due to strong patient demand [7][8] - **Patient Initiations**: Increased from approximately 100 in 2024 to over 300 in 2025, with expectations for further growth in 2026 [7] - **Revenue Timing**: Revenue growth is anticipated as more patients are initiated and treatment sites become fully productive [9] Profitability and Investment - **Peak Spending**: 2025 is expected to be the peak year of spending for the Casgevy franchise, with a focus on investments in gentler conditioning agents and in vivo HSC delivery [10][11] - **Profitability Outlook**: While the timeline for profitability is uncertain, CRISPR is committed to driving towards it through strategic investments [10][11] Clinical Programs and Data Updates - **CTX310 (ANGPTL3)**: - Early data shows an 80% reduction in ANGPTL3, leading to nearly 50% reduction in LDL and 60% in triglycerides [12][13] - Focus on specific patient populations for further data and potential regulatory discussions [15][16] - **CTX320 and CTX321 (Lp(a))**: - Awaiting Horizon data to inform the next steps in development, with CTX320 showing a 73% reduction in Lp levels [18][19] - **CTX340 (Hypertension)**: - Initial dose escalation data expected soon, with promising preclinical results showing nearly 50% reduction in blood pressure [24][25] Safety and Regulatory Considerations - **Safety Profile**: CRISPR emphasizes the safety of its gene editing platform, with minor increases in liver function tests (LFTs) being self-resolving [22][23] - **Regulatory Support**: There is a positive regulatory environment for gene editing technologies, which are viewed as a future solution for curing diseases [22] SyNTase Technology - **New Technology**: SyNTase allows for precise editing at high efficiencies, with initial focus on A1AT indication [27][28] - **Potential Impact**: A1AT gene editing is expected to provide significant improvements in patient outcomes compared to existing therapies [29][30] siRNA Collaboration - **Partnership with Sirius**: CRISPR is collaborating on a Factor XI siRNA program, leveraging advanced technology to create durable and potent siRNAs [31][32] - **Market Potential**: The Factor XI program targets significant markets, including secondary stroke prevention [35][36] ZUGA Cell and CAR T Developments - **ZUGA Cell**: Positioned as a strong asset in the portfolio, with potential in both oncology and autoimmune indications [41][42] - **In Vivo CAR T**: CRISPR is exploring in vivo CAR T technologies, with promising early data and interest from pharmaceutical companies [43][44] Conclusion - CRISPR Therapeutics is strategically positioning itself for growth through a diverse pipeline, strong partnerships, and innovative technologies, with a focus on addressing significant unmet medical needs across various therapeutic areas.

Core Insights - 2026 is anticipated to be a significant year for CRISPR Therapeutics, with potential growth opportunities in the biotech sector [1][2] Company Overview - CRISPR Therapeutics is a leader in gene editing, utilizing a CRISPR-based technique to treat diseases by modifying specific genes [4] - The company has achieved regulatory approval for its first CRISPR-based product, Casgevy, which treats blood disorders such as sickle cell disease and beta thalassemia [5] Revenue Potential - The launch of Casgevy is gaining momentum, with the product having "multi-billion-dollar potential," despite the company sharing profits with partner Vertex Pharmaceuticals [6] - The gene editing treatment process is lengthy, which may delay revenue generation, but the long-term prospects are promising [6] Upcoming Catalysts - In 2026, CRISPR Therapeutics plans to release clinical trial updates for several candidates, including CTX310 and CTX611, as well as initiate trials for new candidates targeting refractory hypertension and alpha-1 antitrypsin deficiency [8] - These updates and milestones could positively impact the stock in the near term and contribute to long-term success [9]

Core Insights - Casgevy, the gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in Q4 revenue and $116 million for the full year, with 64 patients receiving infusions in 2025, including 30 in Q4 [1] - The initiation of treatment for 147 patients globally in 2025 nearly tripled compared to 2024, indicating strong momentum heading into 2026 [1][2] - William Blair analysts express confidence that the increase in first cell collections will lead to significantly higher revenue in 2026 [2] - The company is advancing its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in H2 2026 [2] - The siRNA-based candidate CTX611 is in Phase 2 trials for knee replacement surgery patients and may have broader applications in thromboembolic diseases [3] - CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, while R&D expenses rose to $83.5 million in Q4, and the net loss widened to $130.6 million from $37.3 million a year earlier [4] - CRISPR Therapeutics shares increased by 8.81% to $53.24 at the time of publication [4]

Financial Performance - CRISPR Therapeutics reported a fourth-quarter 2025 loss of $1.37 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.15, compared to a loss of 44 cents per share in the same quarter last year [1] - Total revenues for the quarter were $0.9 million, significantly missing the Zacks Consensus Estimate of $4.0 million, and down from $35.7 million in the year-ago period, which included $35 million in collaboration revenues from Vertex Pharmaceuticals [2] - Research and development (R&D) expenses increased by 16% year over year to $83.5 million, while general and administrative expenses rose about 2% to $18.4 million [8] Stock Performance - Shares of CRISPR Therapeutics declined in after-market trading due to the wider-than-expected loss, with the stock rising nearly 13% over the past year compared to the industry's 19% growth [3] Product Development and Sales - CRISPR Therapeutics and Vertex Pharmaceuticals' gene therapy, Casgevy, is approved in the U.S. and Europe for sickle cell disease and transfusion-dependent beta thalassemia, with Vertex leading global development and commercialization [5] - Vertex reported Casgevy sales of $54 million in the fourth quarter, up from $16.9 million in the previous quarter, contributing to full-year 2025 sales of $116 million [6] - The company plans to file for label expansions for Casgevy in patients aged five to 11 years in the first half of 2026, utilizing the Commissioner's National Priority Voucher to expedite the FDA review process [11] Pipeline Updates - CRISPR Therapeutics is advancing CAR-T cell therapies, with updates on the candidate zugo-cel expected in the second half of 2026 [12] - The company is also focusing on in-vivo candidates, particularly CTX310 for severe hypertriglyceridemia and refractory hypercholesterolemia, with updates anticipated in the second half of 2026 [13] - A collaboration with Sirius Therapeutics is diversifying the pipeline into RNA therapeutics, with an investigational RNA therapy CTX611 in mid-stage studies for preventing venous thromboembolism, with top-line data expected in the second half of 2026 [14] Financial Position - As of December 31, 2025, CRISPR Therapeutics had cash, cash equivalents, and marketable securities worth $1.98 billion, an increase from $1.94 billion as of September 30, 2025, primarily due to proceeds from common share issuance [10]

Core Insights - CRISPR Therapeutics reported financial results for Q4 and full year 2025, highlighting progress in its clinical and preclinical pipeline, including advancements in autoimmune diseases and oncology, as well as the global uptake of its therapy CASGEVY [1][2] Financial Performance - CASGEVY generated Q4 2025 revenue of $54 million and full year revenue of $116 million, with a significant increase in patient initiations and first cell collections, nearly tripling from 2024 to 2025 [5] - Cash, cash equivalents, and marketable securities totaled $1,975.8 million as of December 31, 2025, up from $1,903.8 million in 2024, primarily due to common share issuance and interest income [14] - R&D expenses for Q4 2025 were $83.5 million, an increase from $71.7 million in Q4 2024, driven by higher licensing fees [14] - The net loss for Q4 2025 was $130.6 million, compared to a net loss of $37.3 million in Q4 2024 [14] Pipeline Developments - The company is advancing its in vivo liver editing portfolio and has made progress with its siRNA collaboration with Sirius Therapeutics [2][4] - CTX310, targeting ANGPTL3, is in Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia, with updates expected in H2 2026 [5] - CTX460, targeting SERPINA1 for alpha-1 antitrypsin deficiency, is expected to enter clinical trials in mid-2026 [5] - Zugo-cel is in ongoing Phase 1 trials for autoimmune diseases and hematologic malignancies, with updates anticipated in H2 2026 [10][17] Market Expansion - CASGEVY is approved in multiple regions, including the U.S., EU, and several Middle Eastern countries, with approximately 90% of U.S. patients having reimbursed access [5] - The company is expanding its regenerative medicine portfolio, including CTX213 for Type 1 diabetes, which has shown promising preclinical efficacy [9] Collaborations - CRISPR Therapeutics has a strategic collaboration with Vertex Pharmaceuticals for CASGEVY, with Vertex leading global development and commercialization [13] - The collaboration with Sirius Therapeutics focuses on developing siRNA therapies, with CTX611 being a key program targeting FXI for thromboembolic disorders [19]

Summary of CRISPR Therapeutics FY Conference Call Company Overview - **Company**: CRISPR Therapeutics (NasdaqGM:CRSP) - **Event**: FY Conference Call on January 12, 2026 - **Focus**: Progress and updates on gene editing technologies and therapies Key Points Industry and Market Position - CRISPR Therapeutics is focused on transforming medicine through gene editing, aiming to develop cures for serious diseases [2][34] - The company has made significant advancements across four franchises, including hemoglobinopathies, in vivo gene editing, CAR-T therapies, and RNA-based therapies [2][3] Hemoglobinopathies - **Casgevy**: An approved product with multi-billion dollar revenue potential, showing a 3x increase in patient initiation and cell collections from 2024 to 2025 [5][6] - Revenue surpassed $100 million, with positive payer coverage in the U.S. and Europe [5][6] - Pediatric data for sickle cell and thalassemia shows promising results, expanding the addressable patient population [6][7] In Vivo Gene Editing - Focus on in vivo gene editing of the liver, with promising data for CTX310 targeting hypercholesterolemia [3][11] - A single infusion can lead to a nearly 50% reduction in LDL cholesterol and a 55% reduction in triglycerides [14][15] - The potential for a multi-billion dollar opportunity in treating cardiovascular diseases [17] CAR-T Therapies - CTX112 shows a 70% complete response rate in oncology settings, with a favorable safety profile [27][28] - The company is exploring maintenance therapies to enhance durability of responses [28] - In vivo CAR-T approaches are being developed, utilizing proprietary lipid nanoparticle systems [30] RNA-Based Therapies - CTX611 targets Factor XI, with a potential to revolutionize anticoagulation therapy, showing a 93% reduction in Factor XI antigen levels [21][23] - The siRNA market is projected to be a $20 billion opportunity, with CRISPR's approach aiming to reduce bleeding risks associated with current therapies [21][24] Regulatory and Future Outlook - The FDA is supportive of gene editing technologies, which may facilitate smoother regulatory pathways for CRISPR's programs [40][41] - The company anticipates pivotal trials for several programs, including A1AT and CTX310, in the coming years [36][39] - Continuous innovation and partnerships are expected to enhance the development of their pipeline [47][48] Financial Considerations - CRISPR aims to reduce healthcare costs through one-time gene editing solutions, potentially pricing therapies below $100,000 [50] - The company is focused on creating pharmacoeconomic benefits through its innovative therapies [50] Societal Impact and Diversity - The company acknowledges the importance of addressing racial and ethnic differences in treatment responses, particularly in hypertension medications [51] AI Integration - AI is being utilized to enhance efficiency in clinical trials and improve gene editing processes, particularly in protein and mRNA design [53] Conclusion - CRISPR Therapeutics is positioned for significant growth with a diverse pipeline of innovative therapies across multiple disease areas, supported by strong market potential and favorable regulatory conditions. The company is committed to continuous innovation and addressing healthcare affordability through its gene editing technologies [34][56]

CRISPR Corporate Update 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 1 Forward-Looking Statements This presentation and related materials may contain statements regarding matters that are not historical facts and are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Suc ...